Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
107.01
+1.76 (1.67%)
Jul 30, 2026, 4:00 PM EDT - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 24 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $127.18. The average 1-year stock price forecast is 18.85% higher than the current stock price, while the lowest is $97 (-9.35%) and the highest is $155 (+44.85%).
Price Target: $127.18 (+18.85%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 18 | 17 | 17 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 23 | 24 | 23 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Hold Initiates $120 | Hold | Initiates | $120 | +12.14% | Jul 30, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $125 → $135 | Buy | Reiterates | $125 → $135 | +26.16% | Jul 28, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $140 | Buy | Maintains | $140 | +30.83% | Jul 16, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $120 → $140 | Buy | Maintains | $120 → $140 | +30.83% | Jul 16, 2026 |
| RBC Capital | RBC Capital | Hold Downgrades $106 → $115 | Hold | Downgrades | $106 → $115 | +7.47% | Jul 13, 2026 |
Financial Forecast
Revenue This Year
85.39M
from 39.21M
Increased by 117.78%
Revenue Next Year
41.02M
from 85.39M
Decreased by -51.96%
EPS This Year
-3.51
from -3.69
EPS Next Year
-4.35
from -3.51
EPS and Forward PE are based on non-GAAP adjusted numbers.